Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of BG00012 in relapsing-remitting multiple sclerosis (phase 3, placebo-controlled, dose comparison)
2006-003696-12Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing BG00012 arms with Placebo arm (2 arms). Primary endpoint: Proportion of subjects relapsed at 2 years. Started Dec 2006; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-003696-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003696-12.